Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.
Genetic: mutation analysis
Other: high performance liquid chromatography
Other: laboratory biomarker analysis
Other: questionnaire administration
|Official Title:||Genetic Epidemiologic Studies of Melanoma in Iceland|
- Feasibility to identify melanoma [ Designated as safety issue: No ]
- Feasibility to detect mutation [ Designated as safety issue: No ]
- Ability to create datasets [ Designated as safety issue: No ]
|Study Start Date:||October 2005|
|Study Completion Date:||February 2009|
|Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
- Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
- Assess the feasibility of mutation detection using sequencing and HPLC.
- Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.
OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00346008
|Iceland Genomics Corporation|
|Reykjavik, Iceland, 105|
|Study Chair:||Alisa Goldstein, PhD||National Cancer Institute (NCI)|